PDS Biotechnology Corporation
PDSB
Price:
$1.665
Market Cap:
$62.29M
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related prot...[Read more]
Industry
Biotechnology
IPO Date
2015-09-30
Stock Exchange
NASDAQ
Ticker
PDSB
PE Ratio
[-1.42]
ROE
[-139.57%]
Current Ratio
[2.84]
Dividend Yield
[0%]
Enterprise Value
[37.20M]
Dividend History
The ROE as of December 2024 (TTM) for PDS Biotechnology Corporation (PDSB) is -139.57%
According to PDS Biotechnology Corporation’s latest financial reports and current stock price. The company's current ROE is -139.57%. This represents a change of 282.61% compared to the average of -36.48% of the last 4 quarters.
PDS Biotechnology Corporation (PDSB) Historical ROE (quarterly & annually)
How has PDSB ROE performed in the past?
The mean historical ROE of PDS Biotechnology Corporation over the last ten years is -63.96%. The current -139.57% ROE has changed 118.22% with respect to the historical average. Over the past ten years (40 quarters), PDSB's ROE was at its highest in in the March 2019 quarter at 27.88%. The ROE was at its lowest in in the December 2022 quarter at -48.94%.
Average
-63.96%
Median
-57.28%
Minimum
-164.33%
Maximum
43.84%
PDS Biotechnology Corporation (PDSB) ROE by Quarter and Year
Discovering the peaks and valleys of PDS Biotechnology Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 246.90%
Maximum Annual ROE = 43.84%
Minimum Annual Increase = -152.30%
Minimum Annual ROE = -164.33%
| Year | ROE | Change |
|---|---|---|
| 2023 | -164.33% | 76.99% |
| 2022 | -92.85% | 246.90% |
| 2021 | -26.77% | -51.09% |
| 2020 | -54.73% | -8.53% |
| 2019 | -59.83% | -56.32% |
| 2018 | -136.96% | 67.96% |
| 2017 | -81.54% | 87.53% |
| 2016 | -43.48% | 89.67% |
| 2015 | -22.93% | -152.30% |
| 2014 | 43.84% | -2.24% |
PDS Biotechnology Corporation (PDSB) Average ROE
How has PDSB ROE performed in the past?
The current ROE of PDS Biotechnology Corporation (PDSB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-94.65%
5-year avg
-79.70%
10-year avg
-63.96%
PDS Biotechnology Corporation (PDSB) ROE vs. Peers
How is PDSB’s ROE compared to its peers?
PDS Biotechnology Corporation’s ROE is less than Mereo BioPharma Group plc (0%), greater than Terns Pharmaceuticals, Inc. (-69.11%), greater than Inozyme Pharma, Inc. (-32.76%), greater than HOOKIPA Pharma Inc. (-88.42%), greater than eFFECTOR Therapeutics, Inc. (-49.25%), less than Enveric Biosciences, Inc. (2.18%), greater than CohBar, Inc. (-201.01%), greater than Ocean Biomedical, Inc. (-58.44%), less than AVROBIO, Inc. (75.64%), less than X4 Pharmaceuticals, Inc. (29.68%), greater than Day One Biopharmaceuticals, Inc. (-32.51%), greater than Elevation Oncology, Inc. (-22.40%), greater than null (-59.73%),
| Company | ROE | Market cap |
|---|---|---|
| 0% | $517.59M | |
| -69.11% | $497.75M | |
| -32.76% | $189.51M | |
| -88.42% | $19.21M | |
| -49.25% | $941.00 | |
| 2.18% | $3.22M | |
| -201.01% | $1.57M | |
| -58.44% | $21.54M | |
| 75.64% | $5.24M | |
| 29.68% | $106.34M | |
| -32.51% | $1.27B | |
| -22.40% | $33.51M | |
| -59.73% | $0 |
Build a custom stock screener for PDS Biotechnology Corporation (PDSB) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like PDS Biotechnology Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
PDS Biotechnology Corporation (PDSB) and other stocks custom spreadsheet templates
The easiest way to analyze a company like PDS Biotechnology Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is PDS Biotechnology Corporation's ROE?
How is the ROE calculated for PDS Biotechnology Corporation (PDSB)?
What is the highest ROE for PDS Biotechnology Corporation (PDSB)?
What is the 3-year average ROE for PDS Biotechnology Corporation (PDSB)?
What is the 5-year average ROE for PDS Biotechnology Corporation (PDSB)?
How does the current ROE for PDS Biotechnology Corporation (PDSB) compare to its historical average?